Home
About
Disclaimer
Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Enter Part of Title

Display #

CVS Caremark Faces Lawsuit Over Dropping Zepbound
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability

Articles

Walking Your Way to Better Blood Sugar Control
Novo Nordisk Announces Positive Results in Phase 3a Trial of IcoSema, a Combination of Semaglutide and Insulin Icodec for Type 2 Diabetes
Exploring the Neuroprotective Potential of GLP-1: A New Frontier in Medical Research
Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Data Analytics for Type 2 Diabetes
Diabetes and Heart Health: A Crucial Connection
Cigna's Bold Step Forward: Making Weight-Loss Medications More Accessible
How GLP-1 Receptor Agonists Can Help You Manage Type 2 Diabetes
Managing Type 2 Diabetes: The Power of Combining GLP-1 Medicines with FreeStyle Libre Technology
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
Join the 5K@EASD Virtual Run/Walk for Diabetes Awareness 2024
Understanding the Link Between GLP-1 Receptor Agonists and Reduced Colorectal Cancer Risk in Type 2 Diabetes Patients
Why mRNAs Are a Good Option for Vaccines
Empowering Type 2 Diabetes Management: Dexcom's CGM Innovations and Clinical Breakthroughs
Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Innovative Weight Loss Medication Shows Promise in Lowering Blood Pressure
FDA Clears Dexcom's Stelo, First Over-the-Counter Glucose Biosensor for Type 2 Diabetes Management
Semaglutide's Breakthrough in Kidney Disease Management

News

October 2025

FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment

Contact Us

How many eyes does a typical person have?

Search

Search

You are here:
Home
JCS/T2D - A Diabetes Journey

Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.

Joomla! is Free Software released under the GNU General Public License.